NCT07527143Recruiting
Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer
Source: ClinicalTrials.gov · Last updated 9 Jul 2026
Brief summary (registry, in English)
This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 25 (estimated)
- First submitted
- 7 Apr 2026
- Start date
- 10 Jun 2026
- Primary completion date
- 10 Jun 2027
- Lead sponsor
- Mayo Clinic
- Diseases
- Endometrial cancer
- NCT number
- NCT07527143
What you commit to
- Study type: Observational
- Planned participants: 25
- From 10 Jun 2026 to the primary completion date, 10 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or current diagnosis of endometrial cancer
Who the study is looking for
- Self-identified Black individuals ≥ 45 years with an intact uterus
- Assigned female sex at birth
- Experience with abnormal uterine or post-menopausal bleeding (defined as vaginal bleeding between periods, heavy vaginal bleeding, vaginal bleeding after menopause, and/or red, brown, or pink colored vaginal discharge after menopause)
- Willing to participate in a 45-minute virtual interview
Age in the registry: 45 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.